Want to see CORT full AI Analyst Report?
Research & Development Expense Breakdown
Allocation of R&D spending across programs and trial stages reveals how Corcept is prioritizing its pipeline—whether cash is focused on late‑stage clinical trials that could produce near‑term approvals and revenue, or on early discovery that points to longer‑term growth. Changes in the mix and absolute R&D spend also signal the company’s cash burn and financing needs, the surface area for regulatory and clinical risk, and how management balances short‑term commercial support with long‑term drug development.R&D spending has clearly shifted away from broad metabolic and pre‑clinical programs into hypercortisolism and oncology, signaling management’s priority to commercialize relacorilant/Lifyorli and advance DAZALS and other late‑stage programs; this aligns with the ROSELLA/DAZALS readouts and management’s raised guidance. The earlier spikes in ALS/MASH investment appear to be transitioning into targeted Phase III activity, but sustained higher R&D (and rising stock‑based comp) will support growth while putting near‑term pressure on profitability and making execution and cash runway key risks.
Date | Oncology | Hypercortisolism | Metabolic Diseases | Pre-Clinical & Early Stage Selective Cortisol Modulators and ALS | Unallocated | Stock Based Compensation |
|---|---|---|---|---|---|---|
Jun 30, 2026 | $18.78M | $5.39M | $3.88M | $6.65M | $12.28M | $6.90M |
Mar 31, 2026 | $14.27M | $24.72M | $4.93M | $5.36M | $11.28M | $5.71M |
Dec 31, 2025 | $11.30M | $28.64M | $6.42M | $4.06M | $9.18M | $5.25M |
Sep 30, 2025 | $15.73M | $26.16M | $7.35M | $3.41M | $10.35M | $5.84M |
Jun 30, 2025 | $11.06M | $20.33M | $11.65M | $4.95M | $7.08M | $5.40M |
Mar 31, 2025 | $8.30M | $17.97M | $11.08M | $8.70M | $8.36M | $6.32M |
Dec 31, 2024 | $10.46M | $25.29M | $10.21M | $11.02M | $8.61M | $4.71M |
Sep 30, 2024 | $13.01M | $14.27M | $10.41M | $9.58M | $7.41M | $4.66M |
Jun 30, 2024 | $11.54M | $14.85M | $8.52M | $11.78M | $7.62M | $4.44M |
Mar 31, 2024 | $17.68M | $10.81M | $10.99M | $8.67M | $6.43M | $3.92M |